Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy of 0.2% propranolol eye drops in newborns with retinopathy of prematurity
2014-005472-29Phase 2Completed
- Sponsor
- Meyer Organics
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of propranolol in retinopathy of prematurity (ROP), sponsored by Meyer Organics. Primary endpoint: Progression to stage 2 plus or 3 plus ROP in zone II. Started Nov 2020; status: completed.
02
Drugs
propranolol
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2014-005472-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005472-29.